The investment follows previous institutional funding raised in February 2023.
Origin Capital
Venture CapitalOrigin Capital is an investment firm that backed Cyclops Marine in early 2019 and coordinated its follow-on funding round.
Portfolio
9
companies
By category
- Uncategorised£20.6M
- BioTech£2.1M
- EnergyTech£1.7M
- LegalTech£1.1M
By location
- Cambridge£22.1M
- United Kingdom£3.4M
Portfolio companies
C
CyTAL
CyTAL develops advanced fuzz-testing software for cyber security product assurance.
Echion Technologies
Echion Technologies develops niobium anode materials for lithium-ion batteries.
I
Inductosense
Inductosense develops wireless sensor technology to monitor pipe corrosion and thickness.
Muve
Muve provides residential conveyancing services supported by process automation.
MS
Myrtle Software
Myrtle Software creates software tools for high-performance computing hardware.
N
Naturemetrics
Naturemetrics uses genetic approaches to assess biodiversity in natural environments.
View all 9 companiesShow fewer
Team
Tim de Vere Green
CEO
Tim is the founder and CEO of Origin Capital Partners and serves as a non-executive director across several companies, alongside board roles with Cambridge Angels.
LinkedInAW
Alastair Wright
Alastair is a partner at Origin Capital, following earlier roles as an NHS medical doctor and a BBC assistant producer.
LinkedIn
Mark Woodhams
Partner
Mark focuses on early stage technology and infrastructure investment as a partner at Origin Capital. He also serves as board chair at Cyclops Marine and board observer at Echion Technologies.
LinkedInRecent investments
$25.0M
The Cambridge-based nanomedicine developer has raised capital to expand its laboratory facilities and accelerate product development for its polyNaut technology.
"We are also proud to be working with the Cystic Fibrosis Foundation on one of our key pipeline programmes, underscoring our commitment to advancing treatments for people with cystic fibrosis and other unmet clinical needs. This fundraise marks a pivotal moment in ViaNautis’s journey and we look forward to advancing the field of gene therapy, while creating substantial value for our shareholders."
Origin Capital has backed the business class seat manufacturer.
£2.1M
Origin Capital co-led the £2.1m funding round for the nanoparticle technology developer.
£200K
Origin Capital has led a seed investment in CyTAL to support the growth of its ProtoCrawler software.
"“We’re delighted to receive an investment from Origin, and the process we have been through to get here has really helped us to validate our future plans and ambitions. We’ve listened carefully to what our customers and the market are telling us, and developed ProtoCrawler accordingly. We look forward to welcoming Origin onto the board and exploiting their insights to help us become a leading player in cyber security product assurance and testing software.”"